How We Grade Longevity Providers: Our Methodology

Longevity medicine is a field selling care ahead of its own evidence. No intervention marketed by a longevity clinic — not rapamycin, not NAD+, not peptides, not plasma exchange — has been shown in a completed randomized trial to extend human lifespan, in part because the methodology to run true human healthspan trials is only now maturing and validated aging endpoints barely exist yet¹. That gap is exactly why a ranking site in this niche has to grade differently than one ranking, say, mattresses. The product being sold is partly real diagnostics and oversight, and partly hope priced like a service. Our job is to separate the two — visibly, and the same way every time.

This page is the rubric. It exists so that our provider rankings are auditable rather than vibes: you can see precisely why CoreAge Rx, Fountain Life, AgelessRx, or a closed clinic like Modern Age landed where it did. We grade every provider on five axes, A through F, then weight them. We don't take payment to change a grade, and we flag our own affiliate relationships in the same breath.

The five axes

| Axis | What it measures | Weight | |---|---|---| | Clinical oversight | Real licensed-clinician involvement: who prescribes, who reviews labs, who follows up | 25% | | Evidence honesty | Whether claims match the human data — or oversell mechanism as outcome | 30% | | Transparency | Clear pricing, clear protocols, no dark-pattern upsells or hidden auto-renewals | 20% | | Price-to-value | What you actually get for the money relative to the band | 15% | | Conflicts of interest | Vertical-pharmacy ownership, supplement margins, undisclosed incentives | 10% |

Evidence honesty carries the most weight on purpose. In a field this far ahead of its proof, the single most important thing a provider can do is tell you the truth about what's proven versus plausible. A clinic with great imaging that markets "reverse aging" scores worse, in our book, than a modest membership that says plainly "this peptide has mechanistic support but no completed human longevity trial."

Axis 1 — Clinical oversight (25%)

The first question is the simplest: is a licensed clinician actually in the loop, and what do they do? We grade up for a named prescribing physician or NP who reviews your labs, adjusts protocols, and is reachable for follow-up. We grade down for "clinician oversight" that amounts to a rubber-stamp questionnaire, or for DTC labs that test and hand you off with no one to call. This is the axis that separates a membership program that prescribes from a lab that only measures.

A perfect score here is rare and doesn't require concierge pricing — a $149/month telehealth membership with a genuinely involved prescriber can earn an A on oversight while a $19,000 concierge clinic loses points if its physician contact is a single intake visit.

Axis 2 — Evidence honesty (30%)

This is the heart of the rubric and the hardest to fake. We read what a provider claims against what the human data actually support, intervention by intervention. The benchmark is calibrated to a simple hierarchy: completed human outcome trials at the top, then human biomarker data, then animal and mechanistic data at the bottom.

To make that concrete, here is the standard we hold claims to:

• •The strongest human outcome data in the entire field belongs to GLP-1 receptor agonists. The SELECT trial showed semaglutide cut major cardiovascular events by roughly 20% in overweight and obese adults without diabetes² — and even that proves cardiovascular risk reduction, not slowed aging. A provider that frames GLP-1s honestly (cardiometabolic benefit, "longevity" still a leap) scores well; one that calls them an anti-aging drug does not. We trace this in detail in GLP-1s for healthspan and longevity.
• •The growth-hormone red flag is automatic. Any provider marketing GH or GH-secretagogue peptides as anti-aging is ignoring a landmark systematic review that found small body-composition changes but no proven functional benefit and significantly more adverse events in healthy older adults³. Selling GH for "vitality" caps the evidence-honesty grade.
• •Biological-age and biomarker claims are graded against what the markers can actually do. Epigenetic clocks like GrimAge genuinely predict lifespan and healthspan at the population level⁴ — but at the individual level their test-retest reliability has been weak enough that a single reading can swing by years on re-measurement, a problem the field has had to engineer around⁵. A provider that sells a one-time clock reading as a precise "true age" you can track month to month is overselling the instrument. We unpack this in do epigenetic clocks actually work.

A provider can lose this axis without saying anything technically false — overselling mechanism as outcome is the most common failure mode, and we grade it as such. For the full proven-vs-hyped map we hold every claim against, see longevity medicine: what's proven vs hyped.

Axis 3 — Transparency (20%)

Can a prospective customer find the price, the protocol, and the catch before handing over a card number? We grade up for published pricing, plain-language protocol descriptions, and honest disclosure of what's experimental. We grade down for "book a consult to learn pricing" walls, auto-renewing memberships buried in fine print, and — specific to this niche — over-screening dressed as thoroughness.

That last one deserves its own line. The whole-body MRI that anchors many concierge pitches is a double-edged screen: a 2026 systematic review of more than 9,000 asymptomatic adults found a confirmed-cancer detection rate of just 1.57%, alongside frequent incidental findings, unstandardized protocols, and no long-term outcome or cost-effectiveness data — concluding the scans "may lead to unnecessary investigations"⁶. A transparent provider tells you that the scan finding real cancer in about 1 in 64 healthy people also flags far more ambiguous spots that drive anxiety and follow-up procedures. A provider that markets it as pure "early detection" loses transparency points.

Axis 4 — Price-to-value (15%)

We don't penalize a provider for being expensive — we penalize it for being expensive relative to what it delivers in its band. A concierge clinic charging $20,000 for imaging and genomics you genuinely can't get elsewhere can score well on value; the same clinic loses points if most of the fee buys unproven bolt-on therapies. A membership is judged on whether its labs, prescribing, and retesting cadence justify the monthly fee versus a cheaper DTC panel plus a separate prescriber. The full cost-benefit logic lives in are longevity clinics worth it.

Axis 5 — Conflicts of interest (10%)

The smallest weight, but a real one. The most common conflict in this niche is the vertical pharmacy: a brand that both recommends a therapy and profits from dispensing it through its own pharmacy. That structure isn't automatically disqualifying — many legitimate telehealth providers dispense in-house — but it has to be disclosed, and it raises the bar on evidence honesty for whatever the company sells at margin. We also dock points for supplement upsells with no human data and for undisclosed influencer or affiliate incentives. To be clear about our own: we earn affiliate revenue from some providers we rank, which is why evidence honesty, not commission, drives the grade — and why our rankings hub shows the full graded field, including red-flagged and closed providers we earn nothing from.

How the grades combine

Each axis gets a letter, converted to points (A=4 down to F=0), multiplied by its weight, and summed into an overall A–F grade. A provider has to clear a floor on evidence honesty and oversight to earn an overall A regardless of how it scores elsewhere — a beautifully transparent clinic that oversells reverse-aging can't buy its way to the top on price and polish. Conversely, a provider with honest claims and real oversight can earn a strong overall grade even at an accessible price point, which is exactly how a physician-overseen peptide/NAD+/GLP-1 membership earns its place against five-figure concierge clinics: real oversight, no $20k diagnostic tax, no unproven reverse-aging claims.

We re-audit graded providers periodically, because pricing, protocols, and claims all change. If a provider quietly adds a "reverse aging" therapy or drops a disclosure, the grade moves. The rubric is the constant; the field isn't.

For the rankings this methodology produces, see our graded longevity provider shortlist.